Company profile: Satellos Bioscience
1.1 - Company Overview
Company description
- Provider of regenerative medicine therapeutics to stimulate or restore muscle regeneration, leveraging the MyoReGenX proprietary discovery platform to identify muscle diseases and generate novel drug candidates; developing small molecule therapeutics for Duchenne muscular dystrophy via a dystrophin-independent pathway and advancing a series of AAK1 inhibitors to clinical trials to restore muscle repair and regeneration.
Products and services
- AAK1 Inhibitors: Clinical-stage series of small-molecule inhibitors advanced to trials, targeting restoration of muscle repair and regeneration in Duchenne muscular dystrophy
- Small Molecule Therapeutics for Duchenne Muscular Dystrophy: Pathway-specific medicines in development to restore muscle tissue growth and repair by regulating a dystrophin-independent mechanism in Duchenne muscular dystrophy
- MyoReGenX™: Proprietary discovery platform architected to identify muscle diseases and generate novel drug candidates that enhance muscle tissue growth and repair
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Satellos Bioscience
Amolyt Pharma
HQ: France
Website
- Description: Provider of peptide-based therapeutics for rare endocrine and metabolic disorders, including Eneboparatide in development for hypoparathyroidism to produce sustained, stable blood calcium; AZP-3813, a peptide growth hormone receptor antagonist in development for acromegaly to suppress IGF1; AZP-40XX monoclonal antibodies targeting PTHR1 in preclinical evaluation for PHPT and HHM; and AZP-3404 that may restore fat and glucose metabolism.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amolyt Pharma company profile →
Cosciens Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical diagnostic products, including Macimorelin, an orally active small molecule to diagnose adult growth hormone deficiency (AGHD), approved by the U.S. FDA and European Commission, and Macimorelin for childhood-onset growth hormone deficiency (CGHD) under development, leveraging its safety profile and clinical success in AGHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cosciens Bio company profile →
Synageva BioPharma
HQ: United States
Website
- Description: Provider of novel, next generation and follow on protein therapeutics developed and commercialized using the proprietary Synageva Expression Platform (SEPTM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synageva BioPharma company profile →
Azafaros
HQ: The Netherlands
Website
- Description: Provider of oral azasugar-based therapeutic agents targeting rare lysosomal storage disorders, including the investigational small molecule nizubaglustat for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. Offers the PRONTO natural history study and the RAINBOW clinical study evaluating nizubaglustat, plus an expanded access policy for AZ-3102 limited to clinical trial participation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azafaros company profile →
Amryt Pharma
HQ: Ireland
Website
- Description: Provider of specialty pharmaceuticals for rare and orphan diseases: Myalept/Myalepta (metreleptin) for leptin deficiency complications in generalized or partial lipodystrophy; Mycapssa (octreotide capsules) for long-term maintenance therapy in acromegaly; Juxtapid/Lojuxta (lomitapide) for adults with HoFH; Filsuvez (Oleogel-S10) for partial-thickness wounds in junctional and dystrophic EB; and AP103, a pre-clinical gene therapy for DEB.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amryt Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Satellos Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Satellos Bioscience
2.2 - Growth funds investing in similar companies to Satellos Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Satellos Bioscience
4.2 - Public trading comparable groups for Satellos Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →